Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

Epicensus

- PMLiVE

Johnson & Johnson to expand dermatology portfolio with $850m Proteologix acquisition

The company will gain access to two treatments for atopic dermatitis

- PMLiVE

UCB shares positive phase 3 results for Zilbrysq in generalised myasthenia gravis

Zilbrysq is the first C5 inhibitor to show a clinically meaningful reduction of fatigue in the rare autoimmune disease

- PMLiVE

UCB’s Bimzelx granted EC approval to treat hidradenitis suppurativa in adults

The regulator’s decision marks Bimzelx’s fourth approved indication within the EU

- PMLiVE

UK survey reveals two-thirds of vitiligo patients struggle with mental health

The Vitiligo Society has launched a campaign to address the lack of awareness and understanding surrounding the condition

- PMLiVE

UCB’s Bimzelx recommended by CHMP to treat hidradenitis suppurativa in adults

The inflammatory skin disease affects an estimated 1% of the population in most studied countries

- PMLiVE

UCB reveals positive phase 3 results for Bimzelx in moderate-to-severe plaque psoriasis

Affecting 90% of psoriasis patients, the chronic autoimmune disease causes red, itchy, scaly patches

- PMLiVE

UCB presents positive long-term results for bimekizumab in hidradenitis suppurativa

The drug was associated with sustained improvements in the signs and symptoms of the inflammatory skin disease

- PMLiVE

MHRA approves UCB’s Rystiggo to treat generalised myasthenia gravis

The autoimmune disease has a global prevalence of 100 to 350 cases per every one million people

- PMLiVE

Pfizer’s Litfulo recommended by NICE as first treatment for severe alopecia areata

Up to 14,000 patients living with the autoimmune disease could benefit from NICE’s decision

- PMLiVE

Almirall gains rights to Novo Nordisk’s IL-21 blocker for dermatological diseases

NN-8828 has been developed up to phase 2 in non-dermatological indications

- PMLiVE

UCB presents positive phase 3 results for bimekizumab in hidradenitis suppurativa

The skin disease affects an estimated 1% of the population in most studied countries

- PMLiVE

Almirall and Microsoft partner to accelerate digital transformation in medical dermatology

The alliance is aimed at advancing the research of solutions for dermatological diseases

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links